Clinical Trial Search

Primary: Concentration of Ertapenem in Colorectal Tissue in mg/kg 3 to 6 Hours After a Single Dose of 1 Gram Ertapenem I.V..

Primary: Time Till Relapse — 7; -8 Days to Relapse — p=<0.05

Primary: Airway Blood Flow — 2.13; 13.05 ΔQaw (ul/min/ml)

Primary: Depressive Symptoms — 12.5; 13.4; 7; 5.2 units on a scale — p=0.42

Primary: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 — -0.38; -0.87; -0.75 percentage of hemoglobin — p=<0.0001

Primary: Change in HbA1c From Baseline — -0.97; 0.13 Percent — p=<0.001

Primary: Percentage of Participants With Clostridium Difficile Infection (CDI) Recurrence — 25.9; 17.4; 15.9; 27.6 Percentage of participants — p=0.3182

Primary: Change in Best Corrected Visual Acuity (BCVA) From Baseline to Month 12 — 6.2; 8.1 Letters (EDTRS) — p=<0.001

Primary: Number of Participants Receiving Mechanical Ventilation — 51; NA participants

Primary: Number of Participants Experiencing an Event in the Composite Endpoint (Asthma-related Death, Asthma-related Intubation or Asthma-related Hospitalization) — 43; 40…

Primary: Change in Left Ventricular End Diastolic Volume (LVEDV) — 16.4; 15.8 mL

Primary: Area Under the Plasma Concentration Time-curve From Zero to the Last Measurable Concentration Time Point (AUClast) of Vemurafenib — 125; 76.7 mcg*h/mL

Primary: Ease of Use and Comfort for Subjects Using the ACTitouch System. — 70.8; 37.5; 89.2; 59.4 Percent of participants

Primary: Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 24 — -21.6 units on a scale — p=<0.0001

Primary: Adverse Events Possibly, Probably or Definitely Related to Study Drug — 2; 2; 3; 2 participants